




PHARMACEUTICAL 2022

Sierra Oncology Inc.
Rank 243 of 466





PHARMACEUTICAL 2022

Sierra Oncology Inc.
Rank 243 of 466

The relative strengths and weaknesses of Sierra Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sierra Oncology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 53% points. The greatest weakness of Sierra Oncology Inc. is the variable Net Income, reducing the Economic Capital Ratio by 83% points.

The company's Economic Capital Ratio, given in the ranking table, is 115%, being 37% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	107,393
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,884
Liabilities, Non-Current	485
Other Assets	1,833
Other Compr. Net Income	0
Other Expenses	-3.0
Other Liabilities	0
Other Net Income	-77
Other Revenues	0
Property and Equipment	141
Research and Development	67,150
Selling, General and Administrative Expense	27,435

Output Variable	Value in 1000 USD
Assets	109,367
Liabilities	13,369
Expenses	94,582
Revenues	0
Stockholders Equity	95,998
Net Income	-94,659
Comprehensive Net Income	-94,659
Economic Capital Ratio	115%